Position in CTMX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$401,625
-$95,729 QoQ
Shares Held
107,100
+1.2% QoQ
Ownership
0.049%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#79
of 178 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CTMX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. CTMX ranks #98 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
315,335 | $17,680,833 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
62,523 | $8,298,677 | |
| 3 | CGON |
CG Oncology, Inc.
|
89,218 | $6,338,938 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
97,610 | $5,891,739 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
61,014 | $5,806,702 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
55,281 | $5,388,791 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
93,981 | $5,339,060 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
110,388 | $5,192,651 |
All Filings in CTMX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $401,625 | 107,100 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $497,354 | 105,820 | Shares | Defined | 2026-05-08 | |
| 2022-03-31 | $179,453 | 67,211 | Shares | Defined | 2022-05-16 | |
| 2021-12-31 | $326,971 | 75,513 | Shares | Defined | 2022-02-09 | |
| 2021-09-30 | $406,451 | 79,853 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $542,031 | 85,629 | Shares | Defined | 2021-08-11 | |
| 2021-03-31 | $646,452 | 83,629 | Shares | Defined | 2021-05-07 | |
| 2020-12-31 | $546,879 | 83,493 | Shares | Defined | 2021-02-03 | |
| 2020-03-31 | $633,549 | 82,601 | Shares | Defined | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||